Navigation Links
FDA Issues Complete Response Letter for Iclaprim

REINACH Switzerland, January 19 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) announces today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for intravenous iclaprim for the treatment of complicated skin and skin structure infections (cSSSI). The FDA indicated in its letter that they cannot approve the application for iclaprim in its current form and that additional clinical data are required to demonstrate efficacy in order to gain approval.

President and CEO Dr Jurgen Raths commented: "After the negative recommendation of the Advisory Committee of last November, the FDA opinion comes as no surprise. We now aim to develop a viable roadmap to approval in close consultation with the FDA. The drastic cost saving measures that we've recently implemented should buy us sufficient time to consider and develop strategic options for progressing iclaprim's development."

In its letter to Arpida, the FDA stated the Company's NDA did not demonstrate the efficacy of iclaprim for treatment of cSSSI within an acceptable non-inferiority margin. The FDA requires additional data to assess the benefits and risks of iclaprim for cSSSI.

To address this deficiency, the FDA requests an additional study or studies to demonstrate effectiveness of iclaprim. An additional study showing non-inferiority of iclaprim to an approved comparator may be sufficient to meet this requirement, depending on the study results.

Moreover, the FDA raised questions related to the drug product, which Arpida believes can be rapidly addressed. In addition, the resubmission should provide updated safety data and labelling information.

Arpida today also announces that the restructuring that was announced late last year, is progressing as planned. In addition, the Board of Directors has decided to decrease its membership in order to reflect the reduced size of the company. In this context, Dr Khalid Islam tendered his resignation and Prof. Axel Kleemann has announced that he will not stand for re-election at the next shareholders' meeting. Arpida wishes to thank both Board members for their valuable contributions. Dr Islam will continue to be available to the company as a senior consultant.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This statement was also released in German. The English original is the binding version.

    Arpida contacts:
    Dr Jurgen Raths, President and CEO Tel: +41-61-417-96-60
    Harry Welten, MBA, CFO and Senior Vice President, Tel: +41-61-417-96-65
    Paul Verbraeken, Head of Corporate Communications, Tel: +41-61-417-96-83

SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
4. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
5. OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.
6. FDA Issues Draft Guidance on Priority Review Vouchers
7. Resverlogix Issues a Management Statement
8. Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
11. Arbitration Panel Issues Ruling in Distribution Dispute
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
Breaking Biology News(10 mins):